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ABSTRACT 14 
Recently it has been reported that reduced levels of salivary lactoferrin (LF) can be a 15 
plausible biomarker for amyloid beta (Aβ) accumulation as in the brain of Alzheimer’s 16 
disease (AD) brains. This could mean that reduced levels of salivary LF act as a trigger for 17 
oral dysbiosis and that low LF levels could change the oral microbiota. A chemical change in 18 
the composition of saliva has not yet been considered as a cause for microbial dysbiosis but 19 
does present an opportunity to view oral dysbiosis as a plausible contributory factor in the 20 
development of AD pathophysiology. Oral dysbiosis has largely been reported as a result of 21 
inadequate oral hygiene and dry mouth in elderly subjects. Here we discuss if the deficiency 22 
of LF in saliva and gingival fluid of AD patients can facilitate proliferation of oral pathogens, 23 
and as a result their spread elsewhere in the body. Additionally, we ask if LF in the AD brain 24 
could be overexposed as a result of chronic infection. Together these outcomes will indicate if 25 
reduced levels of salivary LF can act as a trigger of oral dysbiosis. 26 
 27 
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On the question of whether Alzheimer’s disease (AD) is an infectious (communicable) 37 
disease the research of Olsen and Singhrao [1] and Singhrao and Harding [2] support the 38 
plausibility of AD being a polymicrobial dysbiosis of the host’s microbiome.  39 
 Inadequate oral hygiene and dry mouth are accepted reasons for oral dysbiosis. 40 
However, a change in the composition of saliva has not previously been considered as a cause 41 
for microbial dysbiosis. The reasons for dysbiosis in a host’s oral microbiome could be due to 42 
unknown reasons whilst including those already linked to poor oral hygiene and xerostomia. 43 
Carro et al. [3], using mass spectrometry and ELISA, it was demonstratedshowed for the first 44 
time that early diagnosis of mild cognitive impairment (MCI) and subsequent AD can be 45 
associated with impairment of salivary lactoferrin (LF). Later, Gonzáles-Sánchez et al. [4] 46 
suggested that in salivary deficiency of LF, amyloid beta (Aβ) could be a biomarker of AD as 47 
it correlates with the Aβ load in the brain following its visualization with amyloid-Position-48 
Emission Tomography (PET) neuroimaging. We hypothesize that salivary LF deficiency may 49 
act as an unknown trigger of oral microbial dysbiosis. LF is a glycoprotein present in the 50 
human saliva. It is also found in secretions such as milk, tears and gingival fluid, and in cells 51 
like neutrophils [5] and has a broad spectrum antimicrobial activity. Being an antimicrobial 52 
peptide, LF is considered part of the first line or innate immune defense against infections in 53 
man [6] as it targets bacteria, viruses, fungi, yeasts and protozoa. LF is also an iron chelator 54 
and hence prevents iron deposition. It has the ability to block aggregation of both Aβ and 55 
phosphorylated tau, and rescues neuronal damage in AD brains [7, 8]. For a summary of the 56 
biological functions of LF, see Table 1. 57 
When Aβ accumulation reaches a plateau possibly from both local and peripheral Aβ 58 
pools [9], it indicates the MCI stage or prodromal AD. Following this stage, the pathological 59 
cascade of progressive AD takes over. As an antimicrobial peptide, LF can modulate immune 60 
reactions and inflammation (for a review see Farah et al. [10]).  A plethora of reports 61 
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implicate the immune system as a major player in AD manifestation [11-14]. There is 62 
probably an association between systemic infection and AD where salivary LF is down-63 
regulated like several other factors of systemic immunity [6].  64 
The present paper will discuss (1) if deficiency of LF in saliva and gingival fluid of 65 
AD patients can facilitate proliferation of oral pathogens, (2) if this proliferation can result in 66 
transfer of oral pathogens and tissue inflammatory mediators to the brain, and (3) if LF in the 67 
brain of AD patients could be overexposed as a result of chronic infection. 68 
 69 
Decreased salivary lactoferrin is specific to Alzheimer’s disease 70 
In a recent study Gonzáles-Sánchez et al. [4], who examined the relationship between 71 
salivary levels of LF and cerebral Aβ load by using PET neuroimaging, found that LF could 72 
be used to detect MCI or prodromal AD and distinguish AD from other frontotemporal 73 
dementias (FTDs), with sensitivities and specificities over 87% and 91%, respectively. This 74 
study also indicated that LF represents one of the main first lines of defense against pathogens 75 
and confirmed previous findings that there is an association between AD and the immune 76 
system, and brain infections with bacteria, viruses andor yeasts. These microorganisms can all 77 
be related to increased signs of neuroinflammation in the brain [1, 4, 15]. The study of 78 
Gonzáles-Sánchez et al. [4] was the first to show the diagnostic performance and specificity 79 
of a single saliva-based biomarker for detecting MCI and AD. It demonstrated that salivary 80 
LF levels are reduced in AD and, noteworthy, are associated with the amyloid-PET imaging 81 
profile, even in the prodromal stage. An independent cross-sectional study confirmed 82 
simultaneously the presence of low saliva LF levels in AD, as shown previously [3]. 83 
 84 
Low salivary lactoferrin might be an effect of immunological disturbances in 85 
Alzheimer’s disease 86 
AD subjects have long been recognized to suffer from poor oral health and xerostomia 87 
which is thought to be a side effect of their medication. However, this view is changing as 88 
Bermeji-Pareija et al. [6] proposed that reduced levels of salivary LF might be an effect of 89 
immunological disturbances associated with AD. Two pathways could be responsible for this: 90 
first, AD could be a systemic disorder (or disorders) related to early immunological and low 91 
inflammatory changes, and secondly, systemic immunity changes in AD manifestation could 92 
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be a downstream effect of early AD brain involvement. The authors emphasized that the 93 
general acceptance of low LF as an early AD biomarker would rely on validation of LF levels 94 
in other clinical and population-based studies.  95 
 96 
Deficiency in salivary lactoferrin in Alzheimer’s disease could contribute to dysbiosis of 97 
the oral microbiota 98 
LF is secreted by the serous acinar cells of the major and minor salivary glands. In 99 
whole saliva it also originates from neutrophil granulocytes and from the gingival crevicular 100 
fluid. LF plays an important role in regulating the oral microbiota and the inflammatory state 101 
of the oral mucosa [16]. It contributes to the maintenance of symbiosis in the host-102 
microbiome relationship. In dysbiosis, however, certain bacteria are able to flourish at the 103 
demise of others. Particularly the oral pathogen Porphyromonas gingivalis will take 104 
advantage of iron released from haem in inflamed tissues, and increase in number (Figure 1). 105 
This bacterium has a remarkable effect to initiate dysbiosis even in low concentration [17]. In 106 
dysbiosis, levels of salivary LF are expected to increase whilst the body resolves 107 
inflammation and restores symbiosis [18].  108 
However, when LF levels are low, as seen in AD, dysbiosis is expected to proceed 109 
freely. In a study on the subgingival microbiota of people with cognitive dysfunction 110 
participants with periodontitis had a greater abundance of several bacteria: the highest log2-111 
fold changes were seen for Porphyromonas and Peptostreptococcaceae [19]. Even in aged 112 
subjects with oral dryness, salivary levels of LF and chromogranin A were low [20] and this 113 
may aid spread of oral bacteria to the brain. 114 
Dysbiosis can also contribute to a dormant blood microbiome (atopobiosis) and 115 
directly promote systemic inflammation through amyloidogenic formation and shedding of 116 
inflammagens such as lipopolysaccharides (LPSs) [21]. Dormant, non-growing bacteria are 117 
important features in AD. Their growth in vivo is usually limited by a lack of free iron and 118 
this iron dysregulation could be an important factor in their resuscitation [22]. A simultaneous 119 
iron dysregulation and microbial aberrations could affect the hematological system by 120 
promoting fibrin amyloidogenesis and pathological clotting [23]. 121 
 122 
Lactoferrin in the gingival crevicular fluid 123 
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LF is part of the gingival crevicular fluid secreted from the inflamed periodontium 124 
around teeth harboring supra- and sub-gingival biofilms. Studies have shown that LF can be a 125 
biofilm inhibitor of periodontopathic bacteria in vitro and in vivo [24]. These authors reported 126 
that LF reduced the established biofilm at physiological concentrations. The adjunct use of LF 127 
for the prevention and treatment of periodontal diseases has therefore been suggested [25]. LF 128 
was raised in stimulated whole saliva in subjects with “chronic” periodontitis where it 129 
correlated with probing pocket depths ≥ 6 mm [26]. In a study by Daspher et al. [27], LF 130 
inhibited P. gingivalis biofilm formation by 80% at concentrations above 0.625 µM. P. 131 
gingivalis, which is a Gram-negative anaerobic rod, is considered a keystone bacterium in 132 
periodontitis [28-30]. The antimicrobial protection exerted by LF could be reduced when it is 133 
present in low concentrations, as in AD. Maintaining the flow of saliva and the presence of 134 
antimicrobial substances are important to preserve oral health. As mentioned, in the older 135 
population salivary flow is often reduced, for example as a side effect of drug intake. This 136 
could predispose these persons to systemic infection with periodontal bacteria. 137 
 138 
Periodontal bacteria can degrade lactoferrin by its proteases 139 
LF binds to a high-affinity receptor on periodontal bacteria such as P. gingivalis, 140 
Prevotella intermedia and Prevotella nigrescens. In the case of P. gingivalis, all strains 141 
completely degraded LF under the investigative conditions used, whereas only partial 142 
degradation was seen with P. intermedia and P. nigrescens [31]. The proteases (gingipains) of 143 
P. gingivalis may protect this bacterium against LF in periodontal and systemic sites and thus 144 
serve as important virulence factors.  Alugupalli and Kalfas [32] found in an in vitro study 145 
that the degradation of LF was more extensive by P. gingivalis and Capnocytophaga 146 
sputigena, slow by Capnocytophaga ochracea, Aggregatibacter (Actinobacillus) 147 
actinomycetemcomitans and P. intermedia, and very slow or absent by P. nigrescens, 148 
Campylobacter rectus, Campylobacter sputorum, Fusobacterium nucleatum ssp. nucleatum, 149 
Capnocytophaga gingivalis, Tannerella (Bacteroides) forsythia and Peptostreptococcus 150 
micros. All the P. gingivalis strains tested degraded LF. The degradation was sensitive to the 151 
protease inhibitors cystatin C and albumin. These studies indicated that periodontopathogens 152 
can degrade LF. This could facilitate proliferation of some of the most virulent bacteria in 153 
periodontal infections, and possibly promote AD by systemic spread of these bacteria and 154 
their inflammagens to the brain. Inflammagens from P. gingivalis such as gingipain R1 155 
(RgpA) and LPS have been reported to have major effects on blood clot morphology and 156 
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mechanics thereby driving systemic inflammation [33]. Interestingly, intake of tablets 157 
containing LF (60 mg/d) and lactoperoxidase (7.8 mg/d) improved gingival inflammation and 158 
oral health-related quality of life in healthy adults [34] supporting the concept that low levels 159 
of LF are indicators of dysbiosis. 160 
 161 
Porphyromonas gingivalis in Alzheimer’s disease 162 
Recent work has increasingly focused on AD as a microbial disease, for example 163 
Sochocka et al. [15] and Itzaki et al. [35].  In the oral microbiota, P. gingivalis has attracted 164 
much attention for its possible role in AD (Figure 1) [13, 36-40]. However, it may take a long 165 
time for P. gingivalis to promote development of AD. Thus, Sparks Stein et al. [41], Tzeng et 166 
al. [42] and Chen et al. [43] found that gingivitis and chronic periodontal disease could take 167 
up to 10 years for AD to occur. This may also be the time it takes for Aβ to reach a plateau to 168 
become MCI. 169 
 170 
Low salivary lactoferrin could promote transfer of oral bacteria and tissue 171 
inflammatory mediators to the brain 172 
Each time we chew on a periodontitis-affected tooth there will be a bacteremia. During 173 
a day this can last for a total of 3 hours [44]. The spectrum of oral bacteria in this bacteremia 174 
is wide [45] (Figure 1). Also viruses, bacteriophages and yeasts in the periodontal pocket 175 
could follow the bacteria into the blood stream as well as inflammatory mediators from the 176 
inflamed periodontal tissues [1]. In an elderly person with deteriorated blood-brain barrier, 177 
periodontal microorganisms and inflammatory mediators can reach the brain. Several other 178 
ways than the blood stream can also be used by oral microorganisms for brain transfer [1]. 179 
Periodontal pathogens like P. gingivalis and their main virulence factors, like LPS and 180 
gingipains have been demonstrated in the brain of AD patients and in animal models of AD 181 
[37, 46-48]. It is therefore highly plausible that low salivary LF levels, by reducing innate 182 
immunity, can promote dissemination of periodontitis-related microorganisms and 183 
inflammatory tissue mediators to the brain. In addition, salivary LF is transferred into the 184 
brain via the sublingual route [49]. Low levels of salivary LF may therefore affect the 185 




High concentrations of lactoferrin have initially a protective effect on Alzheimer’s 188 
disease 189 
LF has been considered to have a beneficial effect in AD subjects, but the mechanism 190 
is unclear. A possible way could be through its ability to alleviate the AD pathological 191 
cascade and cognitive decline via modulation of the p-Akt/PTEN (phosphatidylinositol-4,5-192 
bisphosphate 3-kinase (PI3K)/protein kinase B (PKB or Akt)/phosphatase and tensin homolog 193 
(PTEN) pathway [50]. These authors reported a possible protective mechanism of post-LF 194 
administration for 3 months in AD patients’ changes in this pathway. LF probably caused this 195 
by affecting key players of inflammation and oxidative stress involved in AD pathology. It 196 
should also be mentioned that iron dysregulation, which is seen in AD, contributes to 197 
oxidative stress [21]. LF could reduce inflammation and stress by binding iron. 198 
The spread of microorganisms to the brain is controlled by several factors, including 199 
LF which, as mentioned, also has an anti-inflammatory effect, especially associated with the 200 
down-regulation of pro-inflammatory cytokines like IL-6. This reduces local and/or systemic 201 
inflammation [51]. Excessive iron contributes to the deposition of Aβ and the formation of 202 
neurofibrillary tangles, which in turn, promotes the development of AD [7]. LF blocks Aβ-203 
aggregation, tauopathy spread and neuronal damage [7]. It also acts as an iron-binding protein 204 
and is strongly up-regulated in the brains of patients with AD [52]. In transgenic mice with 205 
AD these authors used double-immunofluorescence labelling with antibodies directed against 206 
Aβ and LF, and found LF depositions localized to Aβ plaques and regions of amyloid 207 
angiopathy. Both the intensity and number of LF-positive depositions increased with age. The 208 
up-regulation of LF in the brains of both AD patients and transgenic mice with AD indicated 209 
an important protective role for LF in infected AD-brain tissue [53]. It is tempting to 210 
speculate that the high consumption of LF in AD could lead to reduced LF levels over time, 211 
particularly when AD is promoted by long-term chronic infection. Interestingly, Bermejo-212 
Pareja et al. [6] suggested that LF was downregulated in the saliva of AD patients like several 213 
other factors of systemic immunity.  214 
 215 
Concluding remarks 216 
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If LF is a trigger of oral dysbiosis this makes it plausible that it could be a factor in the 217 
etiology or pathophysiology of AD. It is remarkable that the levels of LF are increased in the 218 
brains of AD patients, at least initially, and reduced in their whole saliva. It may be that the 219 
long-term fight against chronic infection in the brain tends to reduce the level of LF. The 220 
latter scenario could aggravate brain infection. It is also possible that low levels of LF in the 221 
whole saliva of AD patients may affect the LF concentration in the brain since salivary LF is 222 
transferred into the brain via the sublingual route. In mice dietary LF supplementation 223 
prevented memory impairment and reduced Aβ generation, and post LF-administration for 3 224 
months in AD patients alleviated the AD pathological cascade and cognitive decline by 225 
modulating the p-Akt/PTEN pathway. Furthermore, tablets containing LF and lactoperoxidase 226 
improved gingival inflammation and oral health-related quality of life in healthy adults 227 
suggesting LF supplements may be a plausible therapy for AD subjects, together with 228 
effective periodontitis prophylaxis and treatment to prevent systemic spread of periodontal 229 
bacteria.  230 
 Another intriguing aspect is that P. gingivalis, which is a keystone bacterium in 231 
periodontitis, and recently has been associated with AD, has the ability to reduce LF levels 232 
through its gingipains. This could take place in the periodontal pocket, but could also occur in 233 
the brain of AD patients where both P. gingivalis and its gingipains have been detected. 234 
Noteworthy in this context is also the finding that P. gingivalis was the most powerful LF- 235 
degrading bacterium of several periodontal pathogens tested in vitro. It is plausible that P. 236 
gingivalis’ effect on LF could be added to its wide capacity of immune suppression, acting 237 
both in the periodontal pocket and in the AD brain. There are also other proteins and peptides 238 
in saliva but their functions and interactions with the oral microbiome remain to be 239 
determined. Clearly, when the level of whole saliva is reduced, its composition is changed and 240 
this could promote dysbiosis and the risk of associated oral diseases such as caries, gingivitis, 241 
periodontitis and fungal infections, and possibly AD. For now, Carro et al. [3] and Gonzáles-242 
Sánchez et al. [4] have highlighted LF as an Aβ biomarker of AD, and the authors of the 243 
current paper have suggested it to be a plausible trigger of oral dysbiosis.  Further in vivo 244 
research on LF and its functions in causing dysbiosis of host mechanisms in the periodontal 245 
pocket and in the brain of AD patients is required to support our hypothesis.   246 
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Figure 1. Schematic to show how reduced levels of salivary lactoferrin (LF) may be a 412 
plausible trigger of oral biofilm dysbiosis. Oral dysbiosis has largely been seen as a result of 413 
inadequate oral hygiene and xerostomia in elderly subjects. Once the LF level begins to 414 
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decrease, this becomes a vicious cycle for sustained dysbiosis. From here P. gingivalis can 415 
spread, via bacteremia, to disparate body organs, for example the brain. This destabilize the 416 
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Table 1. Physiological properties of lactoferrin (adopted from [5]) 428 
Physiological actions Mechanisms 
Iron‐binding protein Iron absorption, transport and sequestration 
Host defence Activities against pathogens: antibacterial, antifungal, antiparasitic, antiviral 
Anti‐inflammatory and alarming 
Anti‐endotoxin 
Anticancer 
Inhibition of prion accumulation 
Host activities Brain development and neuroprotection: alleviating psychological stress 
Bone formation 
Gastrointestinal development 
Immune actions (innate and adaptive): enhancer and modulator 
Wound healing 
Metabolic Adipocytes differentiation 
Antioxidant: inhibiting lipid peroxidation 
Association with other proteins: osteopontin and others 
Decreasing vasoconstriction 
Enzymatic activities 
Glucose regulation (decreasing hyperglycemia) 
Gut microbiota modulation 
Transcriptional regulator 
Miscellaneous Compounds or metabolites carrier (mainly into brain) 
Vaccine adjuvant 
Possible sAD biomarker 
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